TY - T1 - Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors : Current Status and Future Directions SN - / UR - http://hdl.handle.net/10138/212223 T3 - A1 - Bauer, Sebastian; Joensuu, Heikki A2 - PB - Y1 - 2015 LA - eng AB - Imatinib is strongly positioned as the recommended first-line agent for most patients with advanced gastrointestinal stromal tumor (GIST) due to its good efficacy and tolerability. Imatinib-resistant advanced GIST continues to pose a therapeutic challenge, likely due to the frequent presence of multiple mutations that confer drug resistance. Sunitinib and regorafenib are approved as second- and third-line agents, respectively, for patients whose GIST does not respond to imatinib or who do not to... VO - IS - SP - OP - KW - KIT TYROSINE KINASE; PHASE-II; C-KIT; HSP90 INHIBITOR; PROGNOSTIC-FACTORS; ADJUVANT IMATINIB; RANDOMIZED-TRIAL; DRUG-RESISTANCE; BRAF MUTATIONS; DOSE IMATINIB; 3122 Cancers; 317 Pharmacy N1 - PP - ER -